Advanced Biomedical Technologies Inc. Granted New Patent Strengthening its Core Technology

SHENZHEN, CHINA and NEW YORK, Jan. 30, 2018 (GLOBE NEWSWIRE) -- Advanced Biomedical Technologies Inc. (OTCQB:ABMT), a developer and manufacturer of orthopaedic internal fixation devices, today announced the State Intellectual Property Office of The People’s Republic of China (“SIPO”) has issued the Company a new patent titled “Bone Fracture Plate Made of High Polymer Materials”.   

The company’s subsidiary Shenzhen Changhua Biomedical Engineering Company Limited is entitled for the new patent (ZL 2014 1 0647464.1), which strengthens the Company's position in manufacturing process and related controls using our unique polyamide materials (“PA”).

Ms. Wang Hui, CEO of the company said, “This new patent strengthens our IP rights and enables us to develop new products. The combination of fiber-reinforced technology and bionic structure design, allows the medical devices to contain similar mechanical properties to human bone. The elastic fixation does not produce stress shielding, resulting in good fixation effect and biocompatibility. The devices can stimulate bone tissues to achieve effective biological integration, which will benefit bone regeneration. Our uniquely formulated materials can be widely used in the field of orthopaedic internal fixation in an ever-growing and prospective market which is currently dominated by existing materials such as metal and Poly-Lactic-Acid based devices.”

About Advanced Biomedical Technologies Inc. (OTCQB: ABMT)

Advanced Biomedical Technologies, Inc.’s primary product line includes internal fixation devices consisting of proprietary high grade polymers (polyamide – “PA”). Our products are used in a variety of applications including orthopaedic trauma, sports related medical treatment, or cartilage injuries, and reconstructive dental procedures. During the healing process, the products stimulate new bone growth which replaces the degrading device, leaving newer, stronger bone in the exact location of the injury; thus making the site of the injury stronger and more resistant to recurring damage.

These products provide an alternative to metal implants and overcome the limitations of other re-absorbable fixation devices. The material is utilized in producing human body implant screws, binding wires, rods and related implantation products. With over 15 years of meticulous in clinical trials, the company has developed the internal fixation devices to be clinically effective and safe.

The products and materials that the Company has created differ from competing bio-degradable and metal based products being marketed today by:

-  The ability to control the speed that the device degrades; therefore improving upon the healing time.

-  Eliminating the need for a second surgery to replace device due to infection or other post-operative complications.

-  The capability of being evenly absorbed from outer layer inwards, so that it gives enough restoration time for bone healing and re-growth.

The company is establishing broad and new intellectual property protection schemes around our unique PA product lines, not only on its combination compounds, but also to lead as an outstanding material in the future of clinical activity.

Forward-Looking Statements

This release contains forward-looking statements which are made pursuant to provisions of Section 21E of the Securities Exchange Act of 1934. Investors are cautioned that such statements in this release, including statements relating to regulatory and business strategies, plans and objectives of management and growth opportunities for existing or proposed products, constitute forward-looking statements which involve risks and uncertainties that could cause actual results to differ materially from those anticipated by the forward-looking statements. The risks and uncertainties include, without limitation, risks that product candidates may fail in the clinic or may not be successfully marketed or manufactured, we may lack financial resources to complete development or marketing of our products, government regulatory agencies may interpret the results of studies differently than us, competing products may be more successful, demand for new pharmaceutical products may decrease, the biopharmaceutical industry may experience negative market trends, our continuing efforts to develop bone fixation devices may be unsuccessful, our common stock could be delisted from the over-the-counter market, and other risks and challenges detailed in our filings with the U.S. Securities and Exchange Commission. Readers are cautioned not to place undue reliance on any forward-looking statements which speak only as of the date of this release. We undertake no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this release or to reflect the occurrence of unanticipated events.

Follow us on:





Contact Data